PET tracers for beta-amyloid and other proteinopathies

PET and SPECT of Neurobiological Systems

Volumn , Issue , 2014, Pages 199-212

  Nordberg, Agneta ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84908084414     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-42014-6_8     Document Type: Chapter

References (81)

1. Agdeppa ED, Kepe V, Liu J et al (2001) Binding characteristics of radiofluorinated 6-dialkylamino-2-naphtylen derivatives as positron emission tomography imaging probes for ß-amyloid plaques in Alzheimer's disease. J Neurosci 21:1-5
2. Albert MS, DeKosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:270-279
3. Bacskai BJ, Frosch MP, Freeman SH et al (2007) Molecular imaging with Pittsburgh compound B confirmed at autopsy: a case report. Arch Neurol 64:431-434
4. Bao F, Wicklund L, Lacor PN et al (2012) Different ß-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease of onset and impaired cholinergic activity. Neurobiol Aging 33:825.e1-825.e13
5. Batesman RJ, Xiong C, Benzinger TLS et al (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 365:795-804
6. Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82:239-259
7. Braak H, Braak E (1998) Evolution of neuronal changes in the course of Alzheimer's disease. J Neural Transm Suppl 53:127-140
8. Burrell JR, Hornberger M, Villemagne VL et al (2013) Clinical profile of PIB positive corticobasal syndrome. PLoS One 8:e61025
9. Chetelat G (2013) Aß-independent processes-rethinking preclinical AD. Nat Rev Neurol 9:123-124
10. Chetelat G, Villemagne VL, Pike KE et al (2012) Relationship between memory performance and ß-amyloid deposition at different stages of Alzheimer's disease. Neurodegener Dis 10:141-144
11. Chien DT, Bahri S, Szardenings AK et al (2013) Early clinical PET imaging results with the novel PHF-tau radioligand [18-F]-T807. J Alzheimers Dis 34:457-468. doi: 10.3233/JAD-122059
12. Choi SR, Golding G, Zhuang Z et al (2009) Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med 50:1887-1894
13. Chun-Fang X, Arteaga J, Chen G et al (2013) [18F]T-807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. J Alzheimers Dis 9:1-11
14. Clark CM, Pontocorvo MJ, Beach TG et al (2012) Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-ß plaques: a prospective cohort study. Lancet Neurol 11:669-678
15. Cohen AD, Rabinovici GD, Mathis CA et al (2012) Using Pittsburgh compound B for in vivo PET imaging of fibrillar amyloid beta. Adv Pharmacol 64:27-81
16. Drzezga A, Grimmer T, Henriksen G (2008) Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's diseases. Neuroimage 39:619-633
17. Drzezga A, Grimmer T, Henriksen G (2009) Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 72:1487-1494
18. Dubois B, Feldman HH, Jacova C et al (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6:734-746
19. Dubois B, Feldman HH, Jacova C et al (2010) Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 9:1118-1127
20. Edison P, Rowe CC, Rinne JO et al (2008) Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [ 11 C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 79:1331-1338
21. Engler H, Forsberg A, Almqvist O et al (2006) Two-year follow-up for amyloid deposition in patients with Alzheimer's disease. Brain 129:2856-2866
22. Engler H, Fritzell Santillo A, Wang SX et al (2008) In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging 35:100-106
23. Fleisher AS, Chen K, Quiroz YT et al (2012) Florbetapir PET analysis of amyloid-ß deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurol 11:1057-1065
24. Fleisher AS, Chen K, Liu X et al (2013) Apolipoprotein Ee4 and age on florbetapir positron emission tomography in healthy aging and Alzheimer's disease. Neurobiol Aging 34:1-12
25. Fodero-Tavoletti MT, Okamura N, Furumoto S et al (2011) 18F-THK523: a novel tau imaging ligand for Alzheimer's disease. Brain 134:1089-1100
26. Fodero-Tavoletti MT, Brockschnieder D, Villemagne VL et al (2012) In vitro characterization of [(18)F]-florbetaben, an Abeta imaging radiotracer. Nucl Med Biol 39:1042-1048
27. Forsberg A, Engler H, Almkvist O et al (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29:1456-1465
28. Forsberg A, Almkvist O, Engler H et al (2010) High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res 7:56-66
29. Friedland RP, Majocha RE, Reno JM et al (1994) Development of an anti-A beta monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease. Mol Neurobiol 9:107-113
30. Glenner GG, Wong CW (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885-890
31. Gomperts SN, Locascio JJ, Marquie M et al (2012) Brain amyloid and cognition in Lewy body diseases. Mov Disord 8:965-973
32. Harada R, Okamura N, Furumoto S et al (2013) Comparison of the binding of [18F] THK-523 and other imaging tracers to Alzheimer's disease pathology. Eur J Nucl Med Mol Imaging 40:125-132
33. Hardy JA, Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256:184-185
34. Ikonomovic MD, Klunk WE, Abrahamson EE (2008) Post-mortem correlates of in vivo PIB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 131:1630-1645
35. Jack CR, Knopman DS, Jagust WJ et al (2013a) Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12:207-216
36. Jack CR, Wiste HJ, Lesnick TG et al (2013b) Brain ß-amyloid load approaches a plateau. Neurology 80:1-7
37. Johansson A, Savitcheva I, Forsberg A et al (2008) 11 C-PIB imaging in patients with Parkinson's disease. Parkinsonism Relat Disord 14:345-347
38. Johnson KA, Gregas M, Becker JA et al (2007) Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 62:229-234
39. Johnson KA, Minoshima S, Bohnen NI et al (2013) Appropriate use criteria for amyloid PET: a report of the amyloid imaging task force, the society of nuclear medicine and molecular imaging and the Alzheimer association. Alzheimers Dement 9:1-16
40. Kadir A, Nordberg A (2010) Target-specific PET probes for neurodegenerative disorders relegated to dementia. J Nucl Med 51:1418-1430
41. Kadir A, Marutle A, Gonzalez D et al (2011) Positron emission tomography imaging and clinical progression in relation to pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease. Brain 134:301-317
42. Kadir A, Almkvist O, Forsberg A et al (2012) Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiol Aging 33:198.e1-198.e14
43. Kawas CH, Greenia DE, Bullain SS et al (2013) Amyloid imaging and cognitive decline in nondemented oldest-old: The 90+ study. Alzheimer Dement 9:199-203
44. Klunk WE, Engler H, Nordberg A et al (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55:306-319
45. Knopman DS, Jack Jr CR, Wiste HJ et al (2012) Brain injury markers are not dependent on ß amyloid in normal elderly. Ann Neurol 2012 Nov 23. doi:10.1002/ana.23816. [Epub ahead of print]
46. Koivunen J, Scheinin N, Virta JR et al (2011) Amyloid PET imaging in patients with mild cognitive impairment: a 2 year follow-up study. Neurology 76:1085-1090
47. Laforce R, Rabinovici GD (2011) Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications. Alzheimers Res Ther 3:31
48. Lambert MP, Barlow AK, Chromy BA et al (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95:6448-6453
49. Maetzler W, Liespelt I, Reimold M et al (2009) Cortical PIB binding in Lewy body disease as associated with Alzheimer-like characteristics. Neurobiol Dis 34:107-112
50. Mathis CA, Kuller LH, Klunk WE et al (2013) In vivo assessment of amyloid-ß deposition in nondemented very old subjects. Ann Neurol 73:751-761
51. McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:263-269
52. Mintun MA, LaRossa GN, Sheline YI et al (2006) [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67:446-452
53. Morris JC, Aisen P, Randall J et al (2012) Developing an international network for Alzheimer's research: the Dominantly Inherited Alzheimer Network. Clin Investig 2:975-984
54. Ni R, Gillberg P-G, Bergfors A, Marutle A, Nordberg A (2013) Amyloid tracers detect multiple binding sites in Alzheimer's disease tissue. Brain 136:2217-2227
55. Nordberg A (2004) PET imaging of amyloid in Alzheimer's disease. Lancet Neurol 3:519-527
56. Nordberg A (2011) Molecular imaging in Alzheimer's disease-new perspectives on biomarkers for early diagnosis and drug development. Alzheimer Res Ther 3:34, e.1-9
57. Nordberg A, Rinne J, Kadir A, Långström B (2010) The use of PET in Alzheimer's disease. Nature Rev Neurol 6:68-87
58. Nordberg A, Carter S, Rinne J et al (2013) A European multi-center PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging 40:104-114
59. Okamura N, Furumoto S, Harada R et al (2013) Novel 18F-labeled aryquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med 54:1420-1427
60. Okello A, Koivunen J, Edison P et al (2009) Conversion of amyloid positive and negative MCI to AD over 3 years: a 11C-PIB PET study. Neurology 73:754-760
61. Ostrowitzki S, Deptula D, Thjurfell L et al (2012) Mechanism of amyloid removal with Alzheimer disease treated with gantenerumab. Arch Neurol 69:198-207
62. Pike KE, Savage G, Villemagne VL et al (2007) Beta-amyloid imaging and memory in nondemented individuals: evidence for preclinical Alzheimer's disease. Brain 130:2837-2844
63. Raboinovici GD, Furst AJ, O'Neill JP et al (2007) 11C-PIB PET imaging in Alzheimer's disease and frontotemporal lobar degeneration. Neurology 68:1205-1212
64. Rinne JO, Brooks D, Rossor MN et al (2010) 11C-PIB PET in assessment of change in fibrillar amyloid-beta load in Alzheimer's disease patients treated with babineuzumab: a phase 2 double-blind, placebo controlled, ascending dose study. Lancet Neurol 9:363-372
65. Rosenberg PB, Edell SL, Ross JS et al (2013) Cognition and amyloid load in Alzheimer disease imaged with florbetapir F18 (AV-45) positron emission tomography. Am J Geriatr Psychiatry 21:272-278
66. Rowe CC, Villemagne VL (2013) Brain amyloid imaging. J Nucl Med Technol 41:11-18
67. Rowe CC, Ng S, Ackermann U et al (2007) Imaging ß amyloid burden in aging and dementia. Neurology 68:1718-1725
68. Rowe CC, Ellis KA, Rimajova M et al (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31:1275-1283
69. Sendtner M (2011) TDP-43 multiple targets, multiple disease mechanisms? Nat Neurosci 14:403-405
70. Shankar GM, Li S, Mehta TH (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14:837-842
71. Shimada H, Shinotoh H, Hirano S et al (2013) ß-amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy. Mov Disord 28:169-175
72. Shoghi-Jadid K, Small GW, Agdeppa ED et al (2002) Localization of neurofibrillary tangles and betaamyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 10:24-35
73. Small GW, Kepe V, Ercoli LM et al (2006) PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355:2652-2663
74. Sperling RA, Aisen PS, Beckett LA et al (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute of Aging-Alzheimer Association workgroups on the diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:280-292
75. Tolboom N, Van der Flier WM, Yaqub M et al (2009) Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment. Neurology 73:2079-2085
76. Villemagne VI, Burnham S, Bourgeat P et al (2013) Amyloid ß deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 13:357-367
77. Wengenack TM, Curran GL, Poduslo JF (2000) Targeting Alzheimer amyloid plaques in vivo. Nat Biotechnol 18:868-872
78. Wirth M, madison CM, Rabinovici GD et al (2013) Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not ß-amyloid in cognitive normal older individuals. J Neurosci 33:5553-5563
79. Wolk DA, Price JC, Saxton JA et al (2009) Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 65:557-658
80. Wolk DA, Grachev ID, Buckley C et al (2011) Association between in vivo flourine 18-labeled flumetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol 68:1398-1403
81. Zhang W, Arteaga J, Xashion DK et al (2012) A highly selective and specific PET tracer for imaging of tau pathologies. J Alzheimers Dis 31:602-612